Literature DB >> 26517300

The effect of gabapentin and ketorolac on allodynia and conditioned place preference in antibody-induced inflammation.

H J Park1,2, K Sandor3, J McQueen1,3, S A Woller1,4, C I Svensson3, M Corr4, T L Yaksh1.   

Abstract

BACKGROUND: Glucose-6-phosphate isomerase and collagen type II antibody-induced arthritis models (K/BxN and CAIA, respectively) have an inflammatory and a post-inflammatory phase. Both phases display robust tactile allodynia. In previous work, inflammatory phase allodynia was reversed by gabapentin and ketorolac, whereas in late phase only gabapentin was effective. Here, we sought to determine if the effects of these two drugs during the early and late phases of the two arthritis models were observed in the conditioned place preference (CPP) paradigm, indicating a differential drug effect on the aversive state.
METHODS: Male C57BL/6 mice received K/BxN serum intraperitoneally, while male BALB/c mice received collagen type II antibody cocktail intravenously. After onset of inflammation and allodynia, we assessed effects of i.p. gabapentin (100 mg/kg) or ketorolac (15 mg/kg) using a CPP paradigm: 2 days adaptation, 2 days conditioning (vehicle in morning and drug in afternoon), preference testing on day 5.
RESULTS: Consistent with the effects upon allodynia, both gabapentin and ketorolac produced a preference for the drug-paired compartment in the early phase of the K/BxN model, while gabapentin, but not ketorolac, resulted in a place preference during late phase. In the CAIA model, consistent with differential effects upon allodynia, gabapentin produced a preference in the early phase and a trend in the late phase, whereas ketorolac was ineffective at either time.
CONCLUSIONS: CPP validated the aversive state in the inflammatory and post-inflammatory phases of the K/BxN and CAIA arthritis models and correspondence between the anti-hyperpathic pharmacology as defined by thresholds and CPP.
© 2015 European Pain Federation - EFIC®

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26517300      PMCID: PMC5986296          DOI: 10.1002/ejp.816

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  33 in total

1.  The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain.

Authors:  Hue Jung Park; Yoonki Lee; Jaemin Lee; Chongmin Park; Dong Eon Moon
Journal:  Can J Anaesth       Date:  2006-05       Impact factor: 5.063

Review 2.  Diclofenac: an update on its mechanism of action and safety profile.

Authors:  Tong J Gan
Journal:  Curr Med Res Opin       Date:  2010-07       Impact factor: 2.580

3.  Characterization of the acute and persistent pain state present in K/BxN serum transfer arthritis.

Authors:  Christina A Christianson; Maripat Corr; Gary S Firestein; Anahita Mobargha; Tony L Yaksh; Camilla I Svensson
Journal:  Pain       Date:  2010-08-23       Impact factor: 6.961

4.  The effect of intrathecal gabapentin on pain behavior and hemodynamics on the formalin test in the rat.

Authors:  M H Yoon; T L Yaksh
Journal:  Anesth Analg       Date:  1999-08       Impact factor: 5.108

5.  Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents.

Authors:  M J Field; R J Oles; A S Lewis; S McCleary; J Hughes; L Singh
Journal:  Br J Pharmacol       Date:  1997-08       Impact factor: 8.739

6.  Stimulus properties and antinociceptive effects of selective bradykinin B1 and B2 receptor antagonists in rats.

Authors:  Kenneth J Sufka; Todd J Roach
Journal:  Pain       Date:  1996-07       Impact factor: 6.961

7.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

8.  Dissociated modulation of conditioned place-preference and mechanical hypersensitivity by a TRPA1 channel antagonist in peripheral neuropathy.

Authors:  Hong Wei; Hanna Viisanen; Diana Amorim; Ari Koivisto; Antti Pertovaara
Journal:  Pharmacol Biochem Behav       Date:  2012-12-31       Impact factor: 3.533

9.  QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries.

Authors:  Tuulikki Sokka; Hannu Kautiainen; Sergio Toloza; Heidi Mäkinen; Suzan M M Verstappen; Merete Lund Hetland; Antonio Naranjo; Eva Baecklund; Gertraud Herborn; Rolf Rau; Massimiliano Cazzato; Laure Gossec; Vlado Skakic; Feride Gogus; Stanislaw Sierakowski; Barry Bresnihan; Peter Taylor; Catherine McClinton; Theodore Pincus
Journal:  Ann Rheum Dis       Date:  2007-04-05       Impact factor: 19.103

10.  Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling.

Authors:  Jung-Yoon Choe; Brian Crain; Sarah R Wu; Maripat Corr
Journal:  J Exp Med       Date:  2003-02-17       Impact factor: 14.307

View more
  12 in total

Review 1.  A critical evaluation of validity and utility of translational imaging in pain and analgesia: Utilizing functional imaging to enhance the process.

Authors:  Jaymin Upadhyay; Christian Geber; Richard Hargreaves; Frank Birklein; David Borsook
Journal:  Neurosci Biobehav Rev       Date:  2017-08-12       Impact factor: 8.989

Review 2.  Pros and Cons of Clinically Relevant Methods to Assess Pain in Rodents.

Authors:  Anke Tappe-Theodor; Tamara King; Michael M Morgan
Journal:  Neurosci Biobehav Rev       Date:  2019-03-15       Impact factor: 8.989

3.  Neuraxial TNF and IFN-beta co-modulate persistent allodynia in arthritic mice.

Authors:  Sarah A Woller; Cody Ocheltree; Stephanie Y Wong; Anthony Bui; Yuya Fujita; Gilson Gonçalves Dos Santos; Tony L Yaksh; Maripat Corr
Journal:  Brain Behav Immun       Date:  2018-11-19       Impact factor: 7.217

4.  Targeting intrinsically disordered regions facilitates discovery of CaV3.2 inhibitory peptides for AAV-mediated peripheral analgesia.

Authors:  Seung Min Shin; Justas Lauzadis; Brandon Itson-Zoske; Yongsong Cai; Fan Fan; Gayathri Natarajan; Wai-Meng Kwok; Michelino Puopolo; Quinn H Hogan; Hongwei Yu
Journal:  Pain       Date:  2022-04-14       Impact factor: 7.926

5.  Systemic TAK-242 prevents intrathecal LPS evoked hyperalgesia in male, but not female mice and prevents delayed allodynia following intraplantar formalin in both male and female mice: The role of TLR4 in the evolution of a persistent pain state.

Authors:  Sarah A Woller; Satheesh B Ravula; Fabio C Tucci; Graham Beaton; Maripat Corr; R Rivkah Isseroff; Athena M Soulika; Marianne Chigbrow; Kelly A Eddinger; Tony L Yaksh
Journal:  Brain Behav Immun       Date:  2016-04-01       Impact factor: 7.217

6.  Females have greater susceptibility to develop ongoing pain and central sensitization in a rat model of temporomandibular joint pain.

Authors:  Sébastien Sannajust; Ian Imbert; Victoria Eaton; Terry Henderson; Lucy Liaw; Meghan May; Mary F Barbe; Tamara King
Journal:  Pain       Date:  2019-09       Impact factor: 7.926

Review 7.  Calcium channel modulation as a target in chronic pain control.

Authors:  Ryan Patel; Carlota Montagut-Bordas; Anthony H Dickenson
Journal:  Br J Pharmacol       Date:  2017-04-26       Impact factor: 8.739

8.  Gabapentin-induced drug-seeking-like behavior: a potential role for the dopaminergic system.

Authors:  Yusuf S Althobaiti; Amal Alghorabi; Fahad S Alshehri; Bandar Baothman; Atiah H Almalki; Hashem O Alsaab; Walaa Alsanie; Ahmed Gaber; Hussam Almalki; Abdulrahman S Alghamdi; Ahmad Basfer; Sultan Althobaiti; Ana Maria Gregio Hardy; Zahoor A Shah
Journal:  Sci Rep       Date:  2020-06-26       Impact factor: 4.379

9.  Pain relief by supraspinal gabapentin requires descending noradrenergic inhibitory controls.

Authors:  Dina L Juarez-Salinas; Joao M Braz; Katherine A Hamel; Allan I Basbaum
Journal:  Pain Rep       Date:  2018-07-17

10.  Imbalance of proresolving lipid mediators in persistent allodynia dissociated from signs of clinical arthritis.

Authors:  Benjamin L Allen; Karli Montague-Cardoso; Raffaele Simeoli; Romain A Colas; Silvia Oggero; Bruno Vilar; Peter A McNaughton; Jesmond Dalli; Mauro Perretti; Emanuele Sher; Marzia Malcangio
Journal:  Pain       Date:  2020-09-01       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.